![glp-1 receptor Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Agonists: A Scoping Review glp-1_analogs [TUSOM | Pharmwiki]](https://s3.amazonaws.com/production.scholastica/public/attachments/9c499677-aa6b-4e1e-9360-4d7e41721fd8/large/figure_1._mechanism_of_synthesis_of_glp-1.png)
glp-1 receptor Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Agonists: A Scoping Review glp-1_analogs [TUSOM | Pharmwiki]
Description
Patients concerned about GLP-1 treatment should work directly with their healthcare providers to address specific issues
![glp-1 receptor Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Agonists: A Scoping Review glp-1_analogs [TUSOM | Pharmwiki]](https://tmedweb.tulane.edu/pharmwiki/lib/exe/fetch.php/glp1.png?w=600&tok=baf39c)
Statements Author contributions J-YW and Q-WW wrote the first draft of the manuscript
![glp-1 receptor Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Agonists: A Scoping Review glp-1_analogs [TUSOM | Pharmwiki]](https://www.ahajournals.org/cms/asset/8413f170-eb3f-4766-9e6c-b7a4552604a6/hypertensionaha.120.14868.fig07.jpg)
Obesity Pillars , 11, 100113
![glp-1 receptor Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Agonists: A Scoping Review glp-1_analogs [TUSOM | Pharmwiki]](https://cliffordclinic.com/wp-content/uploads/2025/10/Screenshot-2025-10-31-at-10.43.33-AM.png)
Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X)
![glp-1 receptor Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Agonists: A Scoping Review glp-1_analogs [TUSOM | Pharmwiki]](https://cdn2.caymanchem.com/cdn/cms/caymanchem/PublishingImages/Lists/NewsItems/AllItems/Summary%20of%20insulin%20and%20glucagon%20pathways%20in%20glucose%20homeostasis.png)
Recent research, notably the pivotal SELECT trial, has confirmed their suitability for non-diabetic subjects with obesity and established CVD
![glp-1 receptor Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Agonists: A Scoping Review glp-1_analogs [TUSOM | Pharmwiki]](https://www.mdpi.com/ijms/ijms-26-07239/article_deploy/html/images/ijms-26-07239-g001.png)
